183 related articles for article (PubMed ID: 23990684)
1. 99mTc-sestamibi scintigraphy to monitor the long-term efficacy of enzyme replacement therapy on bone marrow infiltration in patients with Gaucher disease.
Erba PA; Minichilli F; Giona F; Linari S; Dambrosia J; Pierini A; Filocamo M; Di Rocco M; Buffoni F; Brady RO; Mariani G
J Nucl Med; 2013 Oct; 54(10):1717-24. PubMed ID: 23990684
[TBL] [Abstract][Full Text] [Related]
2. Severity of bone marrow involvement in patients with Gaucher's disease evaluated by scintigraphy with 99mTc-sestamibi.
Mariani G; Filocamo M; Giona F; Villa G; Amendola A; Erba P; Buffoni F; Copello F; Pierini A; Minichilli F; Gatti R; Brady RO
J Nucl Med; 2003 Aug; 44(8):1253-62. PubMed ID: 12902415
[TBL] [Abstract][Full Text] [Related]
3. Tc-99m sestamibi bone marrow scintigraphy in Gaucher disease.
Aharoni D; Krausz Y; Elstein D; Hadas-Halpern I; Zimran A
Clin Nucl Med; 2002 Jul; 27(7):503-9. PubMed ID: 12072778
[TBL] [Abstract][Full Text] [Related]
4. Standardization of MRI and Scintigraphic Scores for Assessing the Severity of Bone Marrow Involvement in Adult Patients With Type 1 Gaucher Disease.
Mariani G; Perri M; Minichilli F; Ortori S; Linari S; Giona F; Di Rocco M; Cappellini MD; Guidoccio F; Erba PA
AJR Am J Roentgenol; 2016 Jun; 206(6):1245-52. PubMed ID: 27057587
[TBL] [Abstract][Full Text] [Related]
5. Scintigraphic findings on 99mTc-MDP, 99mTc-sestamibi and 99mTc-HMPAO images in Gaucher's disease.
Mariani G; Molea N; La Civita L; Porciello G; Lazzeri E; Ferri C
Eur J Nucl Med; 1996 Apr; 23(4):466-70. PubMed ID: 8612670
[TBL] [Abstract][Full Text] [Related]
6. Technetium-99m-sestamibi scintigraphy in multiple myeloma and related gammopathies: a useful tool for the identification and follow-up of myeloma bone disease.
Balleari E; Villa G; Garrè S; Ghirlanda P; Agnese G; Carletto M; Clavio M; Ferrando F; Gobbi M; Mariani G; Ghio R
Haematologica; 2001 Jan; 86(1):78-84. PubMed ID: 11146575
[TBL] [Abstract][Full Text] [Related]
7. [Enzyme replacement therapy in Gaucher disease: monitoring visceral and bone changes with MRI].
Tóth J; Szücs FZ; Benkö K; Maródi L
Orv Hetil; 2003 Apr; 144(16):749-55. PubMed ID: 12778625
[TBL] [Abstract][Full Text] [Related]
8. Scintigraphic monitoring of reticuloendothelial system in patients with type 1 Gaucher disease on enzyme replacement therapy.
Lorberboym M; Pastores GM; Kim CK; Hermann G; Glajchen N; Machac J
J Nucl Med; 1997 Jun; 38(6):890-5. PubMed ID: 9189137
[TBL] [Abstract][Full Text] [Related]
9. Bone marrow involvement in Gaucher disease at MRI : what long-term evolution can we expect under enzyme replacement therapy?
Fedida B; Touraine S; Stirnemann J; Belmatoug N; Laredo JD; Petrover D
Eur Radiol; 2015 Oct; 25(10):2969-75. PubMed ID: 25875285
[TBL] [Abstract][Full Text] [Related]
10. Is there a role for scintigraphic imaging of bone manifestations in Gaucher disease? A review of the literature.
Mikosch P; Kohlfürst S; Gallowitsch HJ; Kresnik E; Lind P; Mehta AB; Hughes DA
Nuklearmedizin; 2008; 47(6):239-47. PubMed ID: 19057797
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Bone Marrow Infiltration in Non-Neuropathic Gaucher Disease Patients with Use of Whole-Body MRI--A Retrospective Data Analysis.
Laudemann K; Moos L; Mengel KE; Lollert A; Reinke J; Brixius-Huth M; Wagner D; Düber C; Staatz G
Rofo; 2015 Dec; 187(12):1093-8. PubMed ID: 26200566
[TBL] [Abstract][Full Text] [Related]
12. Gaucher disease status and treatment assessment: pilot study using magnetic resonance spectroscopy bone marrow fat fractions in pediatric patients.
Degnan AJ; Ho-Fung VM; Wang DJ; Ficicioglu C; Jaramillo D
Clin Imaging; 2020 Jul; 63():1-6. PubMed ID: 32120306
[TBL] [Abstract][Full Text] [Related]
13. Effect of enzyme replacement therapy with imiglucerase on BMD in type 1 Gaucher disease.
Wenstrup RJ; Kacena KA; Kaplan P; Pastores GM; Prakash-Cheng A; Zimran A; Hangartner TN
J Bone Miner Res; 2007 Jan; 22(1):119-26. PubMed ID: 17032149
[TBL] [Abstract][Full Text] [Related]
14. The clinical course of untreated Gaucher disease in 22 patients over 10 years: hematological and skeletal manifestations.
Piran S; Roberts A; Patterson MA; Amato D
Blood Cells Mol Dis; 2009; 43(3):289-93. PubMed ID: 19793665
[TBL] [Abstract][Full Text] [Related]
15. [A retrospective study on enzyme replacement therapy in patients with Gaucher disease].
Duan YL; Zhang YH; Zang Y; Shi HP; Zhang WM; Hu YM
Zhonghua Er Ke Za Zhi; 2006 Sep; 44(9):653-6. PubMed ID: 17217655
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of treatment response to enzyme replacement therapy with Velaglucerase alfa in patients with Gaucher disease using whole-body magnetic resonance imaging.
Laudemann K; Moos L; Mengel E; Lollert A; Hoffmann C; Brixius-Huth M; Wagner D; Düber C; Staatz G
Blood Cells Mol Dis; 2016 Mar; 57():35-41. PubMed ID: 26852653
[TBL] [Abstract][Full Text] [Related]
17. Use of plain radiography to optimize skeletal outcomes in children with type 1 Gaucher disease in Brazil.
Mota RM; Mankin H
J Pediatr Orthop; 2007; 27(3):347-50. PubMed ID: 17414023
[TBL] [Abstract][Full Text] [Related]
18. Velaglucerase alfa for the management of type 1 Gaucher disease.
Morris JL
Clin Ther; 2012 Feb; 34(2):259-71. PubMed ID: 22264444
[TBL] [Abstract][Full Text] [Related]
19. Bone manifestations in neuronopathic Gaucher disease while receiving high-dose enzyme replacement therapy.
Potnis KC; Flueckinger LB; Ha CI; Upadia J; Frush DP; Kishnani PS
Mol Genet Metab; 2019 Feb; 126(2):157-161. PubMed ID: 30448006
[TBL] [Abstract][Full Text] [Related]
20. Magnetic resonance imaging of bone marrow changes in Gaucher disease during enzyme replacement therapy: first German long-term results.
Poll LW; Koch JA; vom Dahl S; Willers R; Scherer A; Boerner D; Niederau C; Häussinger D; Mödder U
Skeletal Radiol; 2001 Sep; 30(9):496-503. PubMed ID: 11587517
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
